ReviewFolia microbiologica2026
Host-pathogen interactions during ESKAPE-mediated urinary tract infections and ventilator-associated pneumonia: a review.
Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) represents one of the most critical healthcare concerns worldwide, specifically amplified by the ESKAPE pathogens, which represent the six most nosocomial pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. The ESKAPE pathogens pose a crucial challenge due to their unique ability to acquire resistance to most of the currently available drugs. Globally, a serious and alarming prevalence trajectory of ESKAPE pathogens has been seen, responsible for healthcare-associated infections, such as urinary tract infection (UTI) and ventilator-associated pneumonia (VAP). These infections are considered one of the major contributors to morbidity and mortality rates worldwide. This review highlights an emerging trend of AMR associated with UTI and VAP in hospital settings. Furthermore, this review discusses the key mediators of host immune response against ESKAPE pathogens involved in causing UTI and VAP. Developing specific therapeutics and enhancing antimicrobial stewardship strategies against these pathogens may contribute to curbing the growing menace of AMR.
Indexed as
Identifiers
42423835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.